Suppr超能文献

万古霉素群体药代动力学分析的最新进展,第一部分:成人篇。

An Update on Population Pharmacokinetic Analyses of Vancomycin, Part I: In Adults.

机构信息

Faculty of Pharmacy, Université de Montréal, Pavillon Jean-Coutu, 2940 chemin de Polytechnique, Montréal, QC, H3T 1J4, Canada.

Laboratoire de Suivi Thérapeutique Pharmacologique et Pharmacocinétique, Faculté de Pharmacie, Université de Montréal, Montréal, QC, Canada.

出版信息

Clin Pharmacokinet. 2020 Jun;59(6):671-698. doi: 10.1007/s40262-020-00866-2.

Abstract

Despite the wide clinical use of vancomycin, controversy remains regarding its optimal dosage regimens. This can be attributed to the large between- and within-subject variability in the pharmacokinetics of vancomycin. This review aimed at providing a synthesis of population pharmacokinetic models of vancomycin in adults, determining the most reported pharmacokinetic models, and identifying various sources of variability in different special subpopulations to better inform vancomycin dosing. We searched PubMed and EMBASE for population pharmacokinetic studies of vancomycin published from January 2011 to May 2019. Inspection of the relevant lists of references was conducted, as well. This search resulted in a total of 30 eligible studies, which were included. One-, two-, and three-compartments models were reported to best describe vancomycin population pharmacokinetics in 13, 14, and 3 studies, respectively. Three-compartment models were implemented in three studies to account for an additional cerebrospinal fluid compartment. The most common predictors were creatinine clearance and bodyweight, in 20 and 13 studies, respectively. Estimated values of vancomycin clearance and total volume of distribution varied widely from 0.334 to 8.75 L/h (0.0054-0.1279 L/h/kg) and from 7.12 to 501.8 L (0.097-6.97 L/kg), respectively. Almost all studies implemented an exponential interindividual variability model, and the highest variability on clearance was 99.2%. In conclusion, this review highlights the wide ranges and the high variability of estimated population pharmacokinetic parameters. This information can help guide dosing in different subpopulations. Yet, additional analyses with pooled subpopulations might be needed to confirm the necessity of modified dosage regimens.

摘要

尽管万古霉素在临床上广泛应用,但关于其最佳剂量方案仍存在争议。这可以归因于万古霉素药代动力学的个体间和个体内变异性很大。本综述旨在综合成人万古霉素的群体药代动力学模型,确定报告最多的药代动力学模型,并确定不同特殊亚人群中各种变异性的来源,以更好地指导万古霉素剂量。我们在 PubMed 和 EMBASE 上搜索了 2011 年 1 月至 2019 年 5 月发表的万古霉素群体药代动力学研究。还检查了相关的参考文献列表。这项搜索共产生了 30 项符合条件的研究,并将其纳入。分别有 13、14 和 3 项研究报告称,单室、双室和三室模型最能描述万古霉素的群体药代动力学。有 3 项研究采用三室模型来解释额外的脑脊液隔室。最常见的预测因子是肌酐清除率和体重,分别在 20 项和 13 项研究中。万古霉素清除率和总分布容积的估计值差异很大,范围从 0.334 到 8.75 L/h(0.0054-0.1279 L/h/kg)和 7.12 到 501.8 L(0.097-6.97 L/kg)。几乎所有的研究都实施了指数个体间变异性模型,而清除率的最高变异性为 99.2%。总之,本综述强调了估计的群体药代动力学参数的广泛范围和高度变异性。这些信息可以帮助指导不同亚人群的剂量。然而,可能需要对汇总的亚人群进行额外的分析,以确认修改剂量方案的必要性。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验